Daré Bioscience to Participate in Two Upcoming Conferences

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson's participation in two upcoming conferences focused on women’s health. The Informa Connect Women’s Healthcare Access & Innovation Digital Conference will take place on September 21, 2022, featuring a presentation on non-hormonal female contraception. The Longwood Healthcare Leaders Fall Webconference is scheduled for September 22, 2022, and will include a panel on innovative partnerships. Daré aims to advance products that enhance women's health.

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences.

Informa Connect Women’s Healthcare Access & Innovation Digital Conference
September 21, 2022, 1:15-1:45 PM Eastern Time
	Presentation: Novel Approaches to Non-Hormonal Female Contraception
	Sabrina Martucci Johnson, President and CEO, Daré Bioscience

To learn more about the event and register, visit: https://informaconnect.com/womens-healthcare-access-innovation/

Longwood Healthcare Leaders Fall Webconference
September 22, 2022, 12:15-12:45 PM Eastern Time
	Panel: Innovative Partnerships
	Brian McVeigh, CEO, Code Bio (moderator)
	Ken Drazan, Chairman and CEO, Arsenal Biosciences
	Sabrina Martucci Johnson, President and CEO, Daré Bioscience
	Jason Kelly, CEO, Ginkgo Bioworks
	Matthias Müllenbeck, VP, Head, Global BD & Alliance Management, EMD Serono
	Jennifer Petter, PhD, Chief Innovation Officer, Arrakis Therapeutics

Longwood Healthcare Leaders meetings are by invitation only. To learn more about the event, view the agenda, and request an invitation, visit www.longwoodhealthcareleaders.com.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.

Daré’s first FDA-approved product, XACIATO^TM (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene^®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra^®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Evoke Canale
jake.robison@evokegroup.com
619.849.5383

Source: Daré Bioscience, Inc.

FAQ

What is Daré Bioscience's participation in the Informa Connect conference?

Daré Bioscience's CEO, Sabrina Martucci Johnson, will present on non-hormonal female contraception at the Informa Connect Women’s Healthcare Access & Innovation Digital Conference on September 21, 2022.

When is Daré Bioscience speaking at the Longwood Healthcare Leaders Fall Webconference?

Sabrina Martucci Johnson will participate in the Longwood Healthcare Leaders Fall Webconference on September 22, 2022.

What is the focus of Daré Bioscience's upcoming presentations?

Daré Bioscience's presentations will focus on innovative approaches to women's health, specifically non-hormonal contraception and innovative partnerships.

What is the significance of the conferences for Daré Bioscience?

The conferences provide a platform for Daré Bioscience to showcase its leadership in women’s health innovation and to network with industry leaders.

What does Daré Bioscience specialize in?

Daré Bioscience specializes in developing innovative products for women’s health, including contraception, fertility, and sexual health.